Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the’276 patent,) entitled, “Halogenated psilocybin derivatives and methods of using.”

Enveric’s ’276 patent includes claims that appear relevant to the Bretisilocin (GM-2505) molecule currently in clinical trials, which AbbVie agreed to acquire on August 25, 2025 in a definitive transaction valued at up to $1.2 billion (AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline).

The Gilgamesh PGR petition specifically targets claims that may be relevant to Bretisilocin and other claims of the ‘276 patent. Enveric’s ’276 patent family also includes one additional issued U.S. patent, a pending U.S. application, and related international patent applications in Australia, Canada, China, Europe, Japan, Mexico, and South Korea.

The Enveric ’276 patent family does not cover the pipeline of Enveric’s proprietary therapeutic candidates, such as EB-003, which are protected under separate, distinct patent families. Enveric’s intellectual property portfolio, including the ’276 patent family, includes 26 issued U.S. patents and a total of 60 pending national and international applications covering five programs.

Enveric’s product pipeline features

• EB-003, a differentiated therapeutic candidate with dual agonism at 5-HT1B and 5-HT2A receptors in development for depression and anxiety, which is advancing toward the filing of an IND to begin human clinical trials;
• The EVM-401 series of small molecules discovered through its proprietary research platform; and
• Three programs and related patent portfolios that have been successfully out-licensed to third parties for development^1,2,3.

Under those licenses, Enveric is eligible to receive aggregate upfront, development, and sales milestones potentially totaling up to $205 million, plus royalties on future sales.